CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
Droxidopa +1 moredrug
Likely dose
Droxidopa 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03115827
NCT03115827Phase 4Completed
CompareCT.gov

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Vanderbilt University Medical Center·interventional·Posted Apr 14, 2017·Updated Jan 27, 2020

In Brief

A Phase 4 clinical trial evaluating Droxidopa and Carbidopa for Parkinson Disease. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to find out whether droxidopa, a medication that increases norepinephrine levels, may be effective in improving some aspects of cognition and movement in Parkinson's disease (PD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
CollaboratorsH. Lundbeck A/S, American Academy of Neurology

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 14, 2017
Enrollment StartApr 18, 2017
Primary CompletionDec 21, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.2 years ago

Interventions

Droxidopadrug

Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day

Carbidopadrug

Carbidopa 200mg twice a day